Investor Presentaiton

Business Highlights - The "4IN" Strategy Fosun Pharma maintained solid revenue and operating performance growth in 1H22 from increased sales volume of products launched in last 3 years, sales in Covid-19 related products and effective control of marketing expenses Improving Product Portfolio INnovation Serplulimab Injection (PD-1) for MSI-H was approved in China; sqNSCLC, EC- SCLC and ESCC indications were accepted by the NMPA. SCLC was granted FDA Orphan-drug Designation Entered into a strategic callaboration with Genuine Biotech to develop and exclusively commercialize Azvudine, the first domestic small molecule anti Covid-19 oral drugs Yi Kai Da was approved for LBCL second-line therapy clinical trials by NMPA in August 2022. The second CAR T cell therapy product FKC889 for MCL is in the clinical stage in China mRNA Covid-19 vaccine sales around 8 million doses in Hong Kong, Macau and Taiwan region in 1H22 Products launched in 1H22: 2 innovative medicine/new indication (Serplulimab MSI- H indication, Rituximab RA indication); 14 innovative medicine/indication approved IND Revenue from products launched in the last three years is over 25% in 1H22 INternationalization Enhancing Global Operating RMB7,592 million revenue from regions outside Chinese Mainland and other countries, accounting for 35.58% of the total revenue. Overseas commercialization team with over 1,400 employees. Entered into the collaboration and license agreement with Amgen for the exclusive right to commercialize OtezlaⓇ and ParsabivⓇ in Chinese Mainland, another collaboration case with reputable MNC Henlius entered into the license agreement with companies including Organon, Eurofarma and Getz Pharma to cover the main biologics market including the U.S., EU and other emerging markets with international partners Sublicensed from MPP to manufacture both drug substance and product and commercialize COVID-19 oral drugs Molnupiravir and Paxlovid in agreed low- and middle-income countries Building the 2nd headquarter in the U.S.; has 5 regional distribution hubs in Africa; the largest distribution hub in French-speaking West Africa, the Côte d'Ivoire distribution hub has been put into operation Accelerating strategic upgrade an internal integration . • INtegration Subdivided Pharma Segment into three divisions: Innovative Medicines Divisions, Established Medicines Manufacturing & Supply Division, and Vaccines Division. Manufacturing integration: Henlius Songjiang Facility Plant (1) received GMP certification, increased commercial production capacity from 24,000L to 48,000L; integrating and constructing specialty formulation production facilities in Changde, Xinyi and Changshou, and APIs facilities in Xuzhou and Chongqing Med Tech: Sisram strengthened global direct sales teams. Direct sales revenue accounts for 64.8% of the total revenue in 1H22, compared to 59.7% in 1H21. Integrating of Medical Diagnosis Segment to improve the R&D and manufacturing capabilities of diagnostic instruments Intelligent Operation Driven by Digital Transformation INtelligentization Upgrading the R&D digital platform INNOX2.0 for collaborative innovation to improve the efficiency of R&D project management and explore Al-driven R&D Providing integrated online and offline healthcare services to become the leader of family active health

View entire presentation